Drugs / BMS-817378
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00792558 | Jan 2009 → Nov 2010 | cancer | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-817378 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00792558 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545050 ↗1“Hepatocyte growth factor receptor inhibitor” CHEMBL3545050 ↗ |
| Route | Oral | “Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily” NCT00792558 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL3545050 ↗ |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL3545050 ↗ |